Compare WHWK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHWK | ALXO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 172.8M |
| IPO Year | 2017 | 2020 |
| Metric | WHWK | ALXO |
|---|---|---|
| Price | $3.01 | $0.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $7.71 | $4.60 |
| AVG Volume (30 Days) | 366.3K | ★ 1.1M |
| Earning Date | 11-09-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.02 | 26.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,145,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $0.86 |
| 52 Week High | $5.50 | $2.66 |
| Indicator | WHWK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 37.77 |
| Support Level | $2.88 | $0.86 |
| Resistance Level | $3.88 | $1.34 |
| Average True Range (ATR) | 0.21 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 12.50 | 14.25 |
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.